TALON, a phase III b study of brolucizumab versus aflibercept in a matched (treat-and-extend) regimen in patients with neovascular age-related macular degeneration: 32-week primary outcomes - Kertes, P; Regillo, C; Kaiser, P K
Im Internet (Stand: 18.03.2024):